Key points (1).

• Precision oncology includes the use of diagnostic and therapeutic strategies combined to benefit a subgroup of patients whose tumors present specific genomic events that stem from molecular alterations susceptible to management with direct therapies. • Up to 18% of patients with cancer benefit from precision oncology. • NTRK1–3 translocations present in different tumors and their directed treatment constitute the most relevant example to demonstrate the usefulness of the value model based on precision oncology.